Stoke Therapeutics (NASDAQ:STOK) Announces Quarterly Earnings Results

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38, Zacks reports. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

Stoke Therapeutics Price Performance

Shares of Stoke Therapeutics stock opened at $7.74 on Wednesday. The firm has a market cap of $418.56 million, a price-to-earnings ratio of -3.69 and a beta of 0.99. The stock has a 50-day simple moving average of $9.44 and a 200-day simple moving average of $11.30. Stoke Therapeutics has a 52-week low of $7.22 and a 52-week high of $17.58.

Insider Buying and Selling at Stoke Therapeutics

In related news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 over the last ninety days. 11.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

STOK has been the subject of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Chardan Capital restated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.